Product Description: CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC50 of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer[1][2].
Applications: Cancer-programmed cell death
Formula: C15H13Cl2NO3
References: [1]Kim MS, et al. Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. Oncotarget. 2017 Aug 10;8(41):70916-70940. /[2]Kim MS, et al. Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis. Oncotarget. 2020 Oct 27;11(43):3863-3885.
CAS Number: 199735-88-1
Molecular Weight: 326.17
Compound Purity: 98.23
Research Area: Cancer
Solubility: DMSO : 250 mg/mL (ultrasonic)
Target: Reactive Oxygen Species
English
Deutsch
